HCG Peptide: The Complete Guide to Human Chorionic Gonadotropin Benefits, Dosage & Uses

What Is the HCG Peptide?

Human chorionic gonadotropin occupies a unique position in modern endocrinology. Although the wellness industry frequently refers to it as an hCG peptide, its molecular structure is that of a heterodimeric glycoprotein with a molecular weight of approximately 36.7 kilodaltons. The alpha subunit, consisting of 92 amino acids, is identical to the alpha chain shared by luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone. The beta subunit, however, is unique to hCG and contains an additional 24-amino-acid carboxy-terminal extension not found in LH, giving the molecule distinct pharmacokinetic properties (Ezcurra & Humaidan, 2014).

Understanding the hCG peptide begins with appreciating how it interacts with the body. The hormone binds to the LH/hCG receptor (LHCGR) found on Leydig cells in the male testes and on granulosa and theca cells in the female ovary. In men, this binding stimulates intratesticular testosterone synthesis. In women, it mimics the natural LH surge that triggers ovulation and supports the corpus luteum during early pregnancy. The molecule’s eight glycosylation sites—compared to only three on LH—give hCG a subcutaneous half-life of 32 to 33 hours, far exceeding LH’s half-life of approximately 30 minutes after intravenous administration. This extended activity makes hCG an ideal pharmacological analog to LH for clinical applications.

Production of hCG begins almost immediately after embryo implantation, with blood levels doubling approximately every 48 to 72 hours during early pregnancy. This rapid rise is the biological basis for home pregnancy tests. Beyond reproduction, hCG has been investigated for roles in angiogenesis, immune tolerance at the maternal-fetal interface, and hormonal optimization in both sexes. The sections that follow explore each of these clinical applications in evidence-based detail, covering everything from hCG injection dosage for testosterone to the controversial hCG diet and the regulatory changes that have reshaped access to this important hormone.

The growing popularity of hCG in men’s health clinics reflects a broader shift toward hormone optimization rather than simple replacement. Where earlier decades saw hCG used almost exclusively in fertility medicine, contemporary practice increasingly leverages the hCG peptide as part of hCG TRT protocols designed to maintain the body’s endogenous hormonal machinery while supplementing testosterone externally. This dual approach—combining exogenous testosterone with hCG to preserve testicular function—represents a more nuanced understanding of male endocrinology than the testosterone-only paradigm that dominated clinical practice for much of the twentieth century. Whether you are a man exploring testosterone optimization, a woman navigating fertility treatment, or a healthcare provider evaluating therapeutic options, a thorough understanding of the hCG peptide’s pharmacology, dosing, and regulatory status is essential for making informed decisions.

Mechanism of Action: How the HCG Peptide Works in the Body

The mechanism of action of the hCG peptide revolves around its ability to activate the LH/hCG receptor with approximately five-fold greater potency than native luteinizing hormone. When hCG binds this G-protein-coupled receptor, it triggers a cyclic AMP signaling cascade that ultimately drives steroidogenesis—the enzymatic conversion of cholesterol into steroid hormones including testosterone, progesterone, and estradiol. This single pathway explains why human chorionic gonadotropin for men can raise testosterone levels and why it serves as a critical fertility tool for women.

Mechanism in Men: Testosterone and Spermatogenesis

In the male body, the hCG peptide acts directly on Leydig cells within the testes. Leydig cells are responsible for producing roughly 95 percent of circulating testosterone, but they require stimulation from LH—or its analog, hCG—to function. When a man begins testosterone replacement therapy, the hypothalamic-pituitary-gonadal axis detects elevated systemic testosterone and reduces its own GnRH and LH secretion through negative feedback. Intratesticular testosterone levels can plummet by as much as 94 percent within weeks of starting TRT, severely impairing spermatogenesis and potentially leading to azoospermia and testicular atrophy (Coviello et al., 2005). By administering exogenous hCG alongside TRT, clinicians can maintain intratesticular testosterone and preserve both testicular size and sperm production.

Mechanism in Women: Ovulation and Luteal Support

In the female reproductive system, hCG serves a different but equally important role. During a natural menstrual cycle, the pituitary gland releases a surge of LH that triggers the release of a mature egg from the ovarian follicle. In assisted reproductive technology, injectable hCG replaces this natural LH surge. Administered as a “trigger shot” when follicles reach 18 to 20 millimeters in diameter, hCG initiates the final maturation of the oocyte and rupture of the follicle. Ovulation typically occurs 36 to 40 hours after the trigger injection, allowing precise timing of egg retrieval in IVF or intercourse in timed protocols. After ovulation, hCG also supports the corpus luteum, the progesterone-producing structure that sustains early pregnancy until the placenta assumes hormonal control at approximately 10 to 12 weeks of gestation.

FDA-Approved Uses of HCG: Indications, Brands, and Prescribing Facts

The Food and Drug Administration has approved hCG for three specific clinical indications, and understanding these approved uses is essential for anyone researching the hCG peptide. These approvals are limited to injectable formulations available only by prescription—no oral, sublingual, or homeopathic hCG product has ever received FDA approval for any purpose.

Pregnyl and Novarel are urinary-derived hCG products extracted and purified from the urine of pregnant women, supplied as lyophilized powder in 10,000 IU vials that require reconstitution with bacteriostatic water before injection. Ovidrel, by contrast, is a recombinant hCG product manufactured using Chinese hamster ovary cell technology, delivered as a 250-microgram prefilled syringe for subcutaneous injection. The recombinant formulation offers more consistent batch-to-batch potency and eliminates the risk of urinary-derived contaminants, though it comes at a higher cost. All three products are prescription-only and require medical supervision during use.

It is worth noting that hCG is frequently prescribed off-label for applications beyond these three approved indications. In men’s health clinics, hCG is routinely used as an adjunct to testosterone replacement therapy for fertility preservation, prevention of testicular atrophy, and symptomatic improvement of hypogonadism—even in men whose testosterone levels exceed the 300 ng/dL threshold set by the American Urological Association. These off-label applications are supported by clinical evidence but do not carry official FDA approval, making informed medical oversight essential.

Human Chorionic Gonadotropin for Men: Testosterone, TRT, and Fertility

The use of human chorionic gonadotropin for men has expanded substantially over the past two decades, driven by rising hypogonadism rates and growing awareness of TRT’s impact on male fertility. Current data indicate that hypogonadism affects approximately 38 percent of men over age 45 and 7 percent of men under 40, with TRT prescriptions tripling between 2001 and 2011 (Lee & Ramasamy, 2018). As more men of reproductive age begin testosterone therapy, the role of hCG as a concurrent or standalone treatment has become increasingly important.

HCG Injection Dosage for Testosterone During TRT

The landmark study by Coviello and colleagues demonstrated that even low-dose hCG co-administration with TRT can dramatically protect intratesticular testosterone levels. In healthy eugonadal men placed on exogenous testosterone, intratesticular testosterone dropped by 94 percent without hCG. When 250 IU of hCG was administered subcutaneously every other day, that decline was limited to just 7 percent. At 500 IU every other day, intratesticular testosterone actually increased by 26 percent above baseline (Coviello et al., 2005). These findings established the rationale for the hCG injection dosage for testosterone protocols now used in clinics worldwide.

Hsieh and colleagues later confirmed that this biochemical preservation translates to functional outcomes: concomitant hCG with TRT preserved spermatogenesis at one-year follow-up, maintaining both sperm count and testicular volume (Hsieh et al., 2013). This evidence underpins the clinical guidelines summarized in the following dosing table.

The data supporting hCG injection dosage for testosterone come from multiple peer-reviewed sources. A 2018 algorithm proposed by Lee and Ramasamy at the University of Miami stratified treatment based on the timeline for desired pregnancy, with dosing ranging from 500 IU to 3,000 IU every other day depending on clinical urgency (Lee & Ramasamy, 2018). This framework remains the most widely referenced protocol in andrology.

HCG Monotherapy: An Alternative to TRT

Not all men with hypogonadal symptoms require exogenous testosterone. A multi-institutional retrospective study by Madhusoodanan and colleagues evaluated 20 men with a mean baseline testosterone of 362 ng/dL who received hCG monotherapy at an average dose of 2,000 IU weekly. Over a median treatment period of six months, mean testosterone improved by 49.9 percent, rising from 362 ng/dL to 520 ng/dL (p = 0.006). Fifty percent of patients reported subjective improvement in libido, energy, and erectile function, with no adverse events recorded (Madhusoodanan et al., 2019). A larger randomized study by Habous and colleagues reported that 94 men receiving 5,000 IU of hCG twice weekly experienced statistically significant testosterone increases at both one and three months (Habous et al., 2018).

These findings position hCG as a viable option for men who wish to avoid TRT’s side effects—including testicular atrophy, polycythemia, and infertility—while still addressing the fatigue, low libido, and erectile dysfunction associated with testosterone deficiency. The question of how long does hCG take to work in males depends on the endpoint measured: serum testosterone typically rises within four to eight weeks, while improvements in energy, mood, and sexual function may take two to four weeks to become noticeable.

Clinicians who specialize in hCG TRT protocols emphasize the importance of baseline lab work before initiating therapy. A comprehensive hormonal panel should include total and free testosterone, estradiol, sex hormone-binding globulin (SHBG), luteinizing hormone, follicle-stimulating hormone, prolactin, and a complete blood count with hematocrit. These values guide both the initial dose selection and ongoing adjustments, as individual responses to hCG vary significantly based on age, body composition, baseline Leydig cell function, and the degree of HPG axis suppression. Follow-up labs at three-month intervals allow providers to track testosterone response, monitor estradiol for potential aromatization, and ensure that hematocrit remains within safe limits.

Recovery from Anabolic Steroid Use

Anabolic androgenic steroid (AAS) use affects an estimated three million American men and can cause prolonged suppression of the HPG axis, resulting in azoospermia that may take months or even years to reverse spontaneously. HCG-based recovery protocols typically begin with 1,500 to 5,000 IU administered two to three times weekly for three to six months. A multi-institutional study showed that azoospermic or severely oligospermic men treated with hCG 3,000 IU every other day, supplemented with clomiphene citrate or recombinant FSH as needed, regained spermatogenesis to a concentration of 22 million sperm per milliliter within a mean of four months (Wenker et al., 2015). Recombinant FSH at 75 to 400 IU every other day may be added for men who do not respond to hCG alone within the first three months.

HCG Peptide for Women: Fertility, Trigger Shots, and Reproductive Health

For women, the hCG peptide plays an indispensable role in assisted reproductive technology and ovulation induction. Its ability to mimic the LH surge makes it the standard trigger agent in both in-vitro fertilization (IVF) and intrauterine insemination (IUI) protocols. Understanding the timing, dosing, and physiology behind the hCG trigger shot is essential for patients navigating fertility treatment.

The HCG Trigger Shot: Timing and Mechanism

The hCG trigger shot is administered when transvaginal ultrasound confirms that the leading follicle has reached approximately 18 to 20 millimeters in diameter after controlled ovarian stimulation with FSH-containing medications such as Gonal-F or Follistim. The injection is precisely timed to occur 36 hours before the planned egg retrieval in IVF or before timed intercourse in natural or medicated cycles. Typical dosing is 5,000 to 10,000 IU intramuscularly for urinary-derived products (Pregnyl or Novarel) or 250 micrograms subcutaneously for recombinant hCG (Ovidrel). The trigger initiates the final maturation of the oocyte, resumption of meiosis, cumulus expansion, and rupture of the follicular wall—the coordinated cascade we recognize as ovulation.

The hCG trigger shot is one of the most time-sensitive injections in reproductive medicine. Administering it too early may yield immature eggs, while delaying it risks premature ovulation and a missed retrieval window. This precision is why fertility clinics monitor follicular growth with serial ultrasounds and blood estradiol levels before selecting the exact trigger time. Patients should discuss the specific hCG trigger shot protocol and timing with their reproductive endocrinologist to ensure the best possible outcome.

Luteal Phase Support and Early Pregnancy

After ovulation, the corpus luteum requires continued stimulation to maintain progesterone production, which is essential for endometrial receptivity and embryo implantation. In natural conception, the implanting embryo itself begins producing hCG within days of attachment, signaling the corpus luteum to continue its hormonal output. In IVF cycles, exogenous hCG or progesterone supplementation may be prescribed during the luteal phase to bridge the gap until the developing placenta assumes progesterone production at approximately 10 to 12 weeks of gestation. This dual role—triggering ovulation and then sustaining the hormonal environment of early pregnancy—makes hCG one of the most versatile molecules in reproductive endocrinology.

The HCG Diet: Evidence, Risks, and FDA Warnings

The hCG diet remains one of the most controversial topics associated with the hCG peptide, and any comprehensive discussion of human chorionic gonadotropin must address it directly. Despite widespread consumer interest, the scientific evidence and regulatory position are clear: the HCG diet does not work as advertised, and FDA-banned OTC products continue to pose genuine health risks.

Origins: The Simeons Protocol

British endocrinologist Albert T. W. Simeons first proposed hCG as a weight loss tool in 1954, publishing the protocol in his book “Pounds and Inches: A New Approach to Obesity.” The Simeons protocol combined daily hCG injections of 125 to 200 IU with a severely restricted 500-calorie-per-day diet divided into two meals. The diet was structured in three phases: a two-day loading phase of high-calorie eating, a three-to-six-week weight-loss phase of hCG injections plus 500 calories daily, and a three-week maintenance phase of gradually increased calories without hCG. Simeons claimed the hormone mobilized stored fat for energy, prevented hunger despite the extreme calorie deficit, and protected lean muscle mass.

What Does the Clinical Evidence Show?

Multiple controlled clinical trials conducted between the 1970s and the 2010s have definitively refuted Simeons’ claims. Studies comparing hCG injections to placebo injections in participants on identical 500-calorie diets consistently found no significant difference in weight loss, fat distribution, hunger levels, or mood between the two groups. A 1995 meta-analysis and subsequent reviews confirmed that any weight loss observed on the hCG diet is attributable entirely to the severe calorie restriction, not to the hormone itself. The hCG peptide does not enhance fat mobilization, suppress appetite, or prevent the muscle loss that inevitably accompanies a very-low-calorie diet (VLCD).

These findings are important because the hCG diet continues to be marketed aggressively online, often using misleading testimonials and pseudo-scientific language. Consumers searching for hCG for weight loss deserve accurate information: a 500-calorie-per-day diet will produce rapid weight loss in virtually anyone, but the results are unsustainable, and the extreme restriction carries significant metabolic and nutritional risks regardless of whether hCG is added to the protocol.

FDA and FTC Enforcement Actions

The FDA’s position is unequivocal: “There are no FDA-approved HCG products for weight loss. HCG has not been demonstrated to be effective therapy in the treatment of obesity.” The agency has joined with the Federal Trade Commission to issue warning letters to manufacturers of over-the-counter homeopathic hCG drops, pellets, and sprays—products that typically contain no actual hCG hormone despite their labeling claims. These products are considered illegal unapproved new drugs and misbranded drugs under federal law. The FDA has also received reports of serious adverse events in individuals using prescription hCG injections off-label for weight loss, including pulmonary embolism, cerebrovascular events, depression, cardiac arrest, and death. The very-low-calorie component of the diet independently increases the risk of gallstone formation, electrolyte imbalances, and cardiac arrhythmias.

HCG Injection Dosage: Complete Protocol Reference

Accurate dosing is critical for safe and effective use of the hCG peptide, and protocols vary substantially depending on the clinical indication. The table below consolidates evidence-based dosing information from peer-reviewed literature and FDA-approved prescribing information. All dosages require a valid prescription and should be administered under direct medical supervision.

The hCG injection dosage for testosterone support on TRT is the most commonly searched dosing question. Clinical data from Coviello and colleagues established that 250 IU subcutaneously every other day is the minimum effective dose to maintain intratesticular testosterone, while 500 IU every other day provides a more robust effect with a 26 percent increase above baseline. For men using hCG as monotherapy without concurrent TRT, a weekly dose of approximately 2,000 IU appears to provide meaningful testosterone elevation with a favorable safety profile, though individual responses vary based on age, baseline hormonal status, and underlying pathology.

Dosing for fertility applications in women follows a different paradigm entirely. The hCG trigger shot is a single large-dose injection designed to replicate the LH surge, with urinary-derived products dosed at 5,000 to 10,000 IU and recombinant hCG (Ovidrel) dosed at 250 micrograms. Timing, rather than ongoing dosing, is the critical variable in these protocols. Your fertility specialist will determine the exact hCG trigger dose based on estradiol levels, follicle count, and individual response to stimulation medications.

How Do You Administer HCG Injections Safely?

Proper injection technique is essential for maximizing the therapeutic effect of the hCG peptide while minimizing discomfort and infection risk. Whether self-administering at home under medical guidance or receiving injections in a clinical setting, the following steps ensure consistent and safe delivery of the medication.

Reconstitution of Lyophilized HCG

Urinary-derived hCG products such as Pregnyl and Novarel are supplied as a freeze-dried (lyophilized) powder that must be reconstituted before injection. The vial typically contains 10,000 IU of hCG. To reconstitute, withdraw the appropriate volume of bacteriostatic water using a sterile syringe—commonly 1 to 2 mL depending on the desired concentration. Inject the diluent into the powder vial, then gently swirl the vial until the powder is fully dissolved. Avoid vigorous shaking, as this can denature the protein. Once reconstituted, the solution should be clear and free of particulate matter. If using a 1 mL reconstitution volume, each 0.1 mL drawn from the vial delivers 1,000 IU of hCG. Recombinant hCG (Ovidrel) requires no reconstitution, as it comes in a prefilled syringe ready for immediate subcutaneous injection.

Injection Technique

For subcutaneous injection, common sites include the lower abdomen (avoiding a two-inch radius around the navel) and the anterior thigh. Cleanse the injection site with an alcohol swab and allow it to dry. Pinch a fold of skin, insert a 27- to 30-gauge, half-inch needle at a 45- to 90-degree angle depending on body composition, inject slowly, and hold for five to ten seconds before withdrawing the needle. Rotate injection sites with each administration to prevent lipodystrophy or persistent irritation. For intramuscular injections, the deltoid or ventrogluteal region is used with a longer 22- to 25-gauge needle inserted at a 90-degree angle into the muscle. Always use a new, sterile needle and syringe for each injection and dispose of sharps in an approved container.

Many patients find subcutaneous administration more comfortable and convenient than intramuscular injection, and clinical evidence suggests that SC delivery provides comparable bioavailability for the hCG peptide. Discuss the preferred injection route with your prescribing physician, as the choice may depend on the specific hCG product being used, the prescribed dose volume, and individual patient comfort.

How Should You Store HCG? Shelf Life and Stability

Proper hCG storage directly impacts the potency and safety of the medication. Because hCG is a protein-based hormone, it is sensitive to temperature extremes, light exposure, and microbial contamination. Following the manufacturer’s storage guidelines is essential for maintaining therapeutic efficacy.

Never freeze hCG in any form, as freezing destroys the protein structure and renders the hormone inactive. Reconstituted hCG should be inspected before each use for discoloration, cloudiness, or particulate matter—any of these signs indicate degradation and the vial should be discarded. When traveling with hCG, use an insulated cooler bag with ice packs to maintain refrigeration temperatures for reconstituted solutions. Store all hCG products away from direct sunlight and out of reach of children. Proper hCG storage habits ensure that each dose delivers the intended therapeutic concentration throughout the treatment course.

Side Effects, Safety Profile, and Contraindications of HCG

Like any hormone therapy, the hCG peptide carries potential side effects that patients should understand before beginning treatment. Most adverse effects are mild and self-limiting, but rare serious complications exist and require immediate medical attention. The clinical studies reviewed for this guide reported a favorable safety profile for hCG at standard therapeutic doses, with the Madhusoodanan et al. (2019) monotherapy trial recording no adverse events across 20 patients over six months of treatment.

Common Side Effects

Serious Side Effects (Rare)

In women receiving hCG for fertility treatment, ovarian hyperstimulation syndrome (OHSS) is the most significant risk. OHSS occurs when the ovaries overrespond to stimulation, producing multiple large follicles and releasing vasoactive substances that cause fluid shifts from the vascular compartment into the abdomen and lungs. Symptoms range from mild abdominal discomfort and bloating to severe pelvic pain, rapid weight gain, shortness of breath, and decreased urine output. Severe OHSS requires hospitalization and can be life-threatening. Risk is highest in women with polycystic ovary syndrome (PCOS) or those who develop a large number of follicles during stimulation.

In men, prolonged use of high-dose hCG can theoretically increase estradiol levels through aromatization of elevated intratesticular testosterone, potentially causing gynecomastia. This risk is typically managed with concurrent aromatase inhibitor therapy such as anastrozole when clinically indicated. Blood clot formation, including deep vein thrombosis and pulmonary embolism, has been reported in rare case studies associated with hCG use, particularly in the context of the very-low-calorie HCG diet. Monitoring for calf swelling, unexplained shortness of breath, or chest pain is advisable during any hCG therapy.

Contraindications

HCG therapy is contraindicated in individuals with hormone-sensitive cancers (prostate, breast, ovarian), precocious puberty, known hypersensitivity to hCG or any component of the formulation, and untreated thyroid or adrenal gland disorders. Women who are already pregnant should not use hCG for weight loss purposes. A thorough medical evaluation, including baseline hormone panels and cancer screening where appropriate, should precede the initiation of any hCG protocol.

HCG Peptide in Bodybuilding and Post-Cycle Therapy

Within the bodybuilding and fitness community, the hCG peptide occupies a specific niche in post-cycle therapy (PCT) protocols. Athletes who use anabolic androgenic steroids experience suppression of the hypothalamic-pituitary-gonadal axis, often resulting in severely reduced natural testosterone production and testicular atrophy. HCG is incorporated into PCT regimens to restart endogenous testosterone production and restore testicular function before transitioning to selective estrogen receptor modulators (SERMs) like clomiphene citrate or tamoxifen.

The rationale is straightforward: AAS-induced suppression eliminates LH signaling to the testes, causing them to go dormant. Administering hCG directly stimulates the Leydig cells, forcing testosterone production regardless of pituitary output. Typical bodybuilding PCT protocols call for 1,500 to 3,000 IU of hCG every other day for two to four weeks, followed by four to six weeks of SERM therapy to reestablish the HPG axis. Research supports this approach: Wenker and colleagues demonstrated that azoospermic men recovering from exogenous testosterone use regained sperm concentrations of 22 million per milliliter within a mean of four months using hCG-based combination therapy (Wenker et al., 2015).

It is critical to emphasize that anabolic steroid use without medical supervision carries significant health risks, and hCG is not a solution to the underlying dangers of AAS abuse. The inclusion of hCG in PCT does not guarantee full recovery of natural hormone production, and up to 10 percent of men may remain azoospermic even with aggressive pharmacological intervention. Any individual using or considering anabolic steroids should work with a qualified endocrinologist or urologist to develop a monitored recovery plan.

Beyond PCT, some bodybuilders use low-dose hCG during an AAS cycle itself rather than waiting until the post-cycle period. The rationale for “on-cycle” hCG at 250 to 500 IU two to three times per week is that maintaining Leydig cell stimulation throughout the cycle prevents full testicular atrophy and makes the subsequent PCT recovery faster and more complete. While this approach lacks large-scale randomized trial data in the bodybuilding population specifically, the principle is supported by the Coviello et al. study demonstrating that concurrent low-dose hCG prevents the catastrophic 94 percent decline in intratesticular testosterone seen with exogenous testosterone alone. Athletes considering this approach should be aware that hCG itself can elevate estradiol through intratesticular aromatization, potentially necessitating an aromatase inhibitor to manage estrogenic side effects such as water retention and gynecomastia.

Can You Still Buy HCG? Legal Status and Regulatory Changes

The regulatory landscape for purchasing hCG has changed dramatically in recent years, and anyone searching to buy hCG needs to understand the current legal framework. The most significant shift occurred on March 23, 2020, when provisions of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) took effect, reclassifying hCG from a drug to a biologic. This reclassification had immediate and far-reaching consequences for both providers and patients.

The 2020 Biologics Reclassification

Under the BPCIA, hCG was reclassified as a biologic because it is extracted from or synthesized from biological sources. This designation means that compounding pharmacies operating under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act can no longer legally compound hCG. Prior to March 2020, compounded hCG was widely available through specialty and telemedicine pharmacies at relatively affordable prices. After the reclassification, patients were forced to transition to brand-name manufactured products, which are significantly more expensive and subject to supply constraints. The practical effect has been reduced access and increased cost for the thousands of men who relied on compounded hCG as part of their testosterone therapy or fertility preservation protocols.

What Products Are Still Available?

Consumers who encounter websites selling hCG without a prescription or offering oral HCG drops, sprays, or pellets should exercise extreme caution. These products either contain no actual hCG hormone or are being sold in violation of federal law. The FDA has taken enforcement action against numerous vendors, and purchasing such products exposes consumers to unknown ingredients, contamination risks, and potential legal consequences. Legitimate hCG can only be obtained through a licensed healthcare provider and dispensed by a licensed pharmacy.

HCG Peptide vs. Other Hormone Therapies: A Clinical Comparison

Patients researching the hCG peptide often want to understand how it compares to other options for testosterone support and fertility. Several pharmaceutical alternatives address overlapping clinical needs, each with distinct mechanisms, advantages, and limitations. The following comparison helps contextualize where hCG fits within the broader treatment landscape.

For men prioritizing fertility, hCG and clomiphene citrate are the two most commonly prescribed alternatives to standard TRT. HCG has the advantage of directly stimulating Leydig cells regardless of pituitary function, making it effective even in hypogonadotropic hypogonadism where clomiphene would fail. Clomiphene, by contrast, works by enhancing the body’s own LH production through hypothalamic signaling and is taken orally rather than by injection. Gonadorelin, a GnRH analog, has emerged as a compounding alternative since hCG became unavailable through compounding pharmacies, though it requires more frequent administration due to its short half-life and pulsatile dosing requirements.

The choice between these therapies depends on several patient-specific factors. Men with intact pituitary function and mild hypogonadism may respond well to clomiphene citrate or enclomiphene, avoiding injections altogether. Those with documented hypogonadotropic hypogonadism—where the pituitary is not producing adequate LH—will benefit most from hCG because it bypasses the pituitary entirely and acts directly on the testes. Men already established on TRT who wish to add fertility preservation should discuss the hCG TRT combination protocol with their provider, as this remains the best-studied approach for maintaining spermatogenesis during exogenous testosterone use. Cost is also a significant consideration: since the 2020 biologics reclassification eliminated compounded hCG, brand-name products have become substantially more expensive, prompting some clinics to explore gonadorelin or enclomiphene as more affordable alternatives despite their thinner evidence base.

What Does the Clinical Evidence Say About the HCG Peptide?

The clinical foundation for hCG use rests on decades of research spanning fertility medicine, andrology, and endocrinology. The following studies represent the most influential evidence informing current hCG prescribing practices and the guidance presented throughout this article.

Taken together, this body of evidence demonstrates that hCG is a well-characterized pharmacological tool with clear utility in male reproductive health. The strongest data support its use as an adjunct to TRT for fertility and testicular preservation, with growing evidence for monotherapy in symptomatic hypogonadism. For women, hCG’s role as an ovulation trigger is supported by decades of clinical use in IVF and IUI programs worldwide, where it remains the standard of care.

HCG Drops vs. Injections: Which Form Actually Works?

One of the most common questions about the hCG peptide involves the difference between hCG drops and hCG injections. The answer is straightforward and supported by both pharmacology and regulatory science: only injectable hCG contains real human chorionic gonadotropin, and only injectable forms are capable of raising blood levels of the hormone to therapeutic concentrations.

HCG is a large glycoprotein molecule of approximately 36.7 kilodaltons. Proteins of this size cannot survive the acidic environment of the stomach or be absorbed intact through the oral or sublingual mucosa. Oral and sublingual hCG drops, even if they contained actual hCG at the time of manufacture, would be broken down by digestive enzymes before reaching the bloodstream. The majority of hCG drops sold over the counter are labeled as homeopathic preparations, meaning they are so highly diluted that they contain essentially no measurable hCG. The FDA has confirmed that “only injections can raise blood levels of hCG” and that homeopathic OTC products are illegal.

For patients considering hCG therapy for any purpose—testosterone support, fertility treatment, or otherwise—injectable hCG prescribed by a licensed physician is the only scientifically valid option. HCG drops, pellets, and sprays marketed online should be avoided entirely, as they provide no therapeutic benefit and may contain unlisted, potentially harmful ingredients.

Frequently Asked Questions About the HCG Peptide

What is the hCG peptide used for?

HCG is FDA-approved for three uses: inducing ovulation in women with infertility, treating selected cases of male hypogonadotropic hypogonadism, and managing prepubertal cryptorchidism. Off-label, physicians prescribe hCG alongside testosterone replacement therapy to preserve fertility and prevent testicular atrophy.

Is HCG FDA-approved for weight loss?

No. The FDA has explicitly stated that there are no FDA-approved HCG products for weight loss. Clinical studies show that any weight loss on the HCG diet comes solely from the 500-calorie-per-day restriction, not from the hormone itself. OTC homeopathic HCG products are considered illegal by the FDA.

What is the typical hCG injection dosage for testosterone support?

For men on TRT who wish to preserve fertility, typical dosing is 250 to 500 IU subcutaneously every other day. For preventing testicular atrophy alone, 1,500 IU weekly is common. For hCG monotherapy in hypogonadal men, approximately 2,000 IU weekly has shown a 49.9 percent increase in testosterone levels over six months.

How long does hCG take to work in males?

Most men notice improvements in energy and libido within two to four weeks. Measurable increases in serum testosterone appear within one to three months. Spermatogenesis recovery after TRT or anabolic steroid use may take three to six months, with some cases requiring up to two years for full recovery.

Can you still buy compounded hCG?

Since March 23, 2020, the Biologics Price Competition and Innovation Act reclassified hCG as a biologic. Compounding pharmacies under sections 503A and 503B can no longer legally compound hCG. Only brand-name products like Pregnyl, Novarel, and Ovidrel remain available by prescription.

What are the side effects of hCG injections?

Common side effects include headache, injection-site discomfort, fatigue, mood swings, and water retention. Serious but rare risks include ovarian hyperstimulation syndrome in women, blood clots, and gynecomastia in men with prolonged high-dose use. All hCG therapy should be medically supervised.

What is the difference between urinary-derived and recombinant hCG?

Urinary-derived hCG products like Pregnyl and Novarel are extracted from the urine of pregnant women and supplied as lyophilized powder requiring reconstitution. Recombinant hCG, sold as Ovidrel, is produced using recombinant DNA technology and comes as a prefilled syringe for subcutaneous injection with more consistent potency.

Does hCG help preserve muscle during weight loss?

No credible scientific evidence supports the claim that hCG preserves muscle mass during calorie restriction beyond what a placebo would provide. Multiple controlled studies have found identical weight loss and body composition outcomes between hCG and placebo groups on the same very-low-calorie diet.

How should hCG be stored after reconstitution?

Unreconstituted hCG powder should be stored at controlled room temperature between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit). After reconstitution with bacteriostatic water, the solution must be refrigerated at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and used within 30 days.

Key Takeaways: What You Need to Know About the HCG Peptide

Human chorionic gonadotropin is one of the most extensively studied hormones in clinical medicine, with applications spanning male testosterone support, female fertility, and reproductive endocrinology. The hCG peptide acts as a potent LH receptor agonist with a half-life of 32 to 33 hours, making it an ideal pharmacological tool for stimulating intratesticular testosterone production and triggering ovulation. For men on TRT, co-administration of as little as 250 IU every other day prevents the dramatic decline in intratesticular testosterone that causes azoospermia and testicular atrophy. As monotherapy, hCG at 2,000 IU weekly has demonstrated a nearly 50 percent increase in serum testosterone with no reported adverse events in clinical study.

Equally important is understanding what hCG cannot do. The hormone is not an effective weight loss agent, and the FDA has explicitly stated that no hCG product is approved for weight management. Over-the-counter drops, pellets, and sprays contain no real hCG and are considered illegal by federal authorities. Since March 2020, compounded hCG is no longer available due to biologics reclassification, leaving brand-name products like Pregnyl, Novarel, and Ovidrel as the only legitimate sources. Any hCG therapy should be undertaken with the guidance of a qualified healthcare provider who can monitor hormone levels, manage side effects, and adjust dosing to achieve optimal outcomes.

If you are considering using hCG for testosterone optimization, fertility preservation, or reproductive health support, consult with a board-certified endocrinologist, urologist, or reproductive specialist to develop a personalized treatment plan based on current evidence and your individual health profile.

The evolving regulatory landscape adds urgency to staying informed. With compounded hCG no longer available and brand-name prices continuing to rise, patients and providers alike must weigh the cost-benefit ratio of hCG against emerging alternatives like gonadorelin and enclomiphene. Regardless of which therapy is selected, the foundational principles remain the same: obtain baseline laboratory values, establish clear treatment goals, monitor response with regular bloodwork, and maintain open communication with your healthcare team. The hCG peptide has earned its place in clinical medicine through decades of robust research, and with proper medical guidance, it continues to offer meaningful benefits for both men and women navigating complex hormonal and reproductive challenges.

References

1. Ezcurra D, Humaidan P. A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology. Reprod Biol Endocrinol. 2014;12:95. doi:10.1186/1477-7827-12-95

2. Lee JA, Ramasamy R. Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. Transl Androl Urol. 2018;7(Suppl 3):S348–S352. doi:10.21037/tau.2018.04.11

3. Madhusoodanan V, et al. Human Chorionic Gonadotropin monotherapy for the treatment of hypogonadal symptoms in men with total testosterone > 300 ng/dL. Int Braz J Urol. 2019;45(5):1008–1012. doi:10.1590/S1677-5538.IBJU.2019.0132

4. Coviello AD, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595–2602. doi:10.1210/jc.2004-0802

5. Hsieh TC, et al. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013;189(2):647–650. doi:10.1016/j.juro.2012.09.043

6. Wenker EP, et al. The Use of HCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Use. J Sex Med. 2015;12(6):1334–1337. doi:10.1111/jsm.12890

7. Habous M, et al. Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study. BJU Int. 2018;122(5):889–897. doi:10.1111/bju.14401

8. U.S. Food & Drug Administration. Questions and Answers on HCG Products for Weight Loss. FDA.gov. Accessed July 2025.

9. U.S. Food & Drug Administration. Avoid Dangerous HCG Diet Products. FDA.gov. Accessed July 2025.

10. Simeons ATW. Pounds and Inches: A New Approach to Obesity. 1954.

11. Pregnyl (chorionic gonadotropin for injection, USP) Prescribing Information. Organon LLC. Revised 2023.

12. U.S. Food & Drug Administration. Notice to Compounders: Changes that Affect Compounding as of March 23, 2020. FDA.gov.

Michael Phelps

Michael is an Air Force veteran and the Marketing Director at PrymaLab. With a specialized background in biochemistry and over 10 years in the biotech industry, he applies military-grade precision to research standards and quality control. Michael is dedicated to bridging the gap between complex scientific studies and practical application, providing accurate, science-backed information on peptide protocols.